Clinical trials: Cardiac Thrombus
Other Acute Illnesses Presenting to the Hospital, Heart Failure
Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
This VA QUERI Partnered Evaluation Initiative will evaluate the impact of an immersive Point-of-care Ultrasound (POCUS) Training Course on provider skill acquisition and retention; the frequency of POCUS use by trained providers…
- Conditions
- Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis
- Trial name
- NCT03296280
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Venous Thrombosis, Atrial Fibrillation
Personalized Warfarin Dosing by Genomics and Computational Intelligence
This study will create a computer program that can be used to help dose a drug called warfarin for the prevention of blood clotting.
- Conditions
- Venous Thrombosis, Atrial Fibrillation, Myocardial Infarction
- Trial name
- NCT00872079
- Testing
- Genomics
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- US Department of Veterans Affairs
Anticoagulants, Atrial Fibrillation
Improving Anticoagulation Control in VISN 1
Over 100,000 VHA patients receive anticoagulants (blood thinners) each year to prevent blood clots (including strokes). Too much anticoagulation increases the risk of serious or even fatal bleeding, and too little anticoagulation…
- Conditions
- Anticoagulants, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- NCT01653405
- Testing
- Multifaceted behavioral intervention
- Where
- United States
- Volunteers
- 1,260,576 people
- Sponsor
- VA Office of Research and Development
Atrial Fibrillation, Venous Thromboembolism
Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients
Warfarin is very effective for the prevention of blood clots (thrombosis). A test of coagulation, the prothrombin time (PT) is used to monitor the effect.
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction
- Trial name
- FORESPEAK-0 (NCT00814177)
- Testing
- warfarin
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Hamilton Health Sciences Corporation
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Atrial Fibrillation, Deep Vein Thrombosis
Weekly Monitoring Strategy of Capillary INR Versus Monthly Monitoring Strategy of Venous INR in Elderly Patients in a Nursing Home.
This primary care study aims to compare the "time in therapeutic range" (TTR) of two strategies for monitoring the international normalized ratio (INR) over 6 months in nursing homes.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Stroke
- Trial name
- INR-CAP (NCT05561244)
- Testing
- Weekly monitoring using the capillary International Normalised Ratio strategy
- Where
- 33 sites in France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Coronary Syndrome
Antithrombotic Effects of Ticagrelor Versus Clopidogrel
The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin and bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and bivalirudin).
- Trial name
- NCT01642238
- Testing
- Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Juan J Badimon
Platelet Inhibition, Coronary Stent Implantation
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode…
- Trial name
- IDEAL-PCI (NCT01515345)
- Testing
- prasugrel or ticagrelor, Clopidogrel
- Where
- Austria
- Volunteers
- 1,008 people
- Sponsor
- Kaiser Franz Josef Hospital
Atrial Fibrillation, Atrial Flutter
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and…
- Conditions
- Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial
- Trial name
- IMPACT (NCT00559988)
- Testing
- Home Monitoring Guided OAC, Physician-Directed OAC
- Where
- 80 sites in United States, Australia and 4 more
- Volunteers
- 2,718 people
- Sponsor
- Biotronik, Inc.
Coronary Artery Bypass
Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
This is a randomized-controlled clinical trial that will randomize 120 patients undergoing clinically-indicated coronary artery bypass graft surgery to prasugrel at a dose of 10 mg daily or matching placebo for 12 months…
- Trial name
- NCT01560780
- Testing
- Prasugrel
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- VA Office of Research and Development
Angioplasty, Cardiovascular Disease
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug Administration (CFDA) on August 10th, 2011.
- Conditions
- Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease
- Trial name
- XP China SAS (NCT01894152)
- Testing
- XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
- Where
- United States
- Volunteers
- 2,002 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Healthy Participants
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable…
- Trial name
- NCT05093790
- Testing
- Ticagrelor, BMS-986141, Aspirin
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Thrombosis
Heart and Hands Study II: A Retrospective Data Collection & Analysis Project
A recent pilot study conducted at HealthEast found use of manual pressure with the SoftSeal hemostatic pad for 15 minutes was successful in 9 out of 10 people fully anticoagluated using 4 French radial sheath.
- Trial name
- NCT02307318
- Testing
- SoftSeal Hemostatic Pad
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- HealthEast Care System
Atrial Fibrillation, Deep Vein Thrombosis
Randomized Trial of Interventions to Improve Warfarin Adherence
The purpose of this research study is to see if a lottery which provides the opportunity to win money, a reminder system using a "Med-eMonitor", or the combination of both might be useful in helping patients to achieve better…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Dilated Cardiomyopathies
- Trial name
- WIN3 (NCT00904982)
- Testing
- Financial Incentive and Med-eMonitor, 2Med-eMonitor
- Where
- 2 sites in United States
- Volunteers
- 268 people
- Sponsor
- University of Pennsylvania
Bleeding Complications
Clopidogrel Monotherapy in Patients With High Bleeding Risk
The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications.
- Trial name
- NCT05223335
- Testing
- Clopidogrel, Prasugrel, Tricagrelor
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Aortic Valve Stenosis, Cardiovascular Diseases
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
The aortic valve is located between the left ventricle and the aorta. Patients with symptomatic, severe aortic valve stenosis conventionally have it surgically replaced requiring direct access to the heart through the chest.
- Conditions
- Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction
- Trial name
- GALILEO-4D (NCT02833948)
- Testing
- Acetylsalicylic acid, Clopidogrel, Rivaroxaban
- Where
- 25 sites in United States, Canada and 5 more
- Volunteers
- 231 people
- Sponsor
- ECRI bv
Aortic Valve Disorder
Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.
This is a prospective, randomized pilot study in patients undergoing Sugical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) to estimate the incidence of reduced leaflet motion and assess the…
- Trial name
- NCT02696226
- Testing
- SAVR Warfarin, SAVR Aspirin, TAVR Warfarin and clopidogrel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Cardiovascular Disease
Cardiovascular Inflammation Reduction Trial
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic…
- Trial name
- CIRT (NCT01594333)
- Testing
- Methotrexate
- Where
- 470 sites in United States, Canada and 1 more
- Volunteers
- 4,786 people
- Sponsor
- Brigham and Women's Hospital